TITLE

Surgery in the tri-modality treatment of small cell lung cancer.: Stage-dependent survival

AUTHOR(S)
Granetzny, Andreas; Boseila, Ahmad; Wagner, Wolfgang; Krukemeyer, Georg; Vogt, Ulf; Hecker, Erich; Koch, Olaf M.; Klinke, Folker
PUB. DATE
August 2006
SOURCE
European Journal of Cardio-Thoracic Surgery;Aug2006, Vol. 30 Issue 2, p212
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract: Objective: Patients with small cell lung cancer (SCLC) are frequently denied surgical treatment despite growing body of evidence for a longer duration of remission and overall survival, if surgical intervention is integrated in a tri-modality therapy concept including chemotherapy, surgery, and radiotherapy. Methods: A retrospective analysis was performed using data derived from 95 patients with SCLC operated upon over a period of 9 years. A subset of these patients was primarily operated upon and being diagnosed as SCLC only after thoracotomy, received radio-/chemotherapy postoperatively (n =64, group I). The second cohort had surgery after neoadjuvant chemotherapy which was continued postoperatively in addition to thoracic and cranial radiotherapy (n =31, group II). The patients in the second group were further divided into two subgroups: complete histological regression of tumor tissue in the mediastinal lymph nodes (group IIA), and those with persistent mediastinal lymph nodal involvement detected after thoracotomy (group IIB). Results: Group I patients had stage I or II disease, whereas group II patients had clinical stage IIIA or IIIB. The overall 30-day mortality rate was as low as 5%. The median survival was 31.3 months for patients in group I, 31.7 months for adjuvant surgery with complete regression of mediastinal nodes (group IIA), and 12.4 months for adjuvant surgery without regression of mediastinal nodes (group IIB). Conclusions: Surgical intervention is promising and warrants prospective trials to be evaluated as an important adjunct to multi-modality therapy regimen in SCLC as regards to its impact on relapse free and overall survival.
ACCESSION #
21665212

 

Related Articles

  • Combination Therapy May Hold Most Benefit for NSCLC Patients.  // RT: The Journal for Respiratory Care Practitioners;Feb2010, Vol. 23 Issue 2, p27 

    The article reports on the study which found that combination therapy provide most benefit for non-small cell lung cancer patients (NSCLC).

  • The role of segmental nodes in the pathological staging of non-small cell lung cancer. Zhen-xuan Li; Hong Yang; Ke-lin She; Ming-xing Zhang; Han-qing Xie; Peng Lin; Lan-jun Zhang; Xiao-dong Li // Journal of Cardiothoracic Surgery;2013, Vol. 8 Issue 1, p1 

    Background Segmental nodes are not examined routinely in current clinical practice for lung cancer, the role of segmental nodes in pathological staging of non-small cell lung cancer after radical resection was investigated. Methods A total of 113 consecutive non-small cell lung cancer patients...

  • Clinical evaluation of systemic inflammatory response syndrome (SIRS) in advanced lung cancer (T3 and T4) with surgical resection Iwasaki, Akinori; Shirakusa, Takayuki; Maekawa, Takafumi; Enatsu, Sotarou; Maekawa, Shinichi // European Journal of Cardio-Thoracic Surgery;Jan2005, Vol. 27 Issue 1, p14 

    Abstract: Objectives: The systemic inflammatory response syndrome (SIRS) is well known to occur in patients who have suffered organ damage or trauma, or undergone surgery. SIRS provides useful information in patients with morbidity after surgery. To date, there has been no report of SIRS after...

  • Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Gridelli, Cesare; Rossi, Antonio; Maione, Paolo // Oncogene;9/29/2003 Review, Vol. 22 Issue 42, p6629 

    Conventional treatment of non-small-cell lung cancer (NSCLC) has apparently reached a plateau of effectiveness in improving the survival of NSCLC patients. Although neoadjuvant and adjuvant therapies in early stages are under investigation and some progress has been achieved in the management of...

  • ANALYSIS OF SYMPTOM CLUSTERS IN WOMEN WITH LUNG CANCER. Brown, Jean; Sarna, Linda; Cooley, Mary; Chernecky, Cynthia // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p192 

    The purpose of this presentation is to demonstrate the use of a unique statistical approach to describe symptom clusters in a multi-site, prospective study of 196 women with nonsmall cell lung cancer who were > 6 months and < 5 years from diagnosis. Average age was 65.4 years (SD=11.4); average...

  • Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Suzuki, Hidemi; Sekine, Yasuo; Yoshida, Shigetoshi; Suzuki, Makoto; Shibuya, Kiyoshi; Yonemori, Yoko; Hiroshima, Kenzo; Nakatani, Yukio; Mizuno, Satoko; Takiguchi, Yuichi; Yoshino, Ichiro // Surgery Today;Jul2011, Vol. 41 Issue 7, p914 

    Purpose: In patients with lung cancer accompanied by idiopathic pulmonary fibrosis (IPF), acute exacerbation of the IPF often occurs after pulmonary resection; however, few studies have been done to identify its preexisting risk factors. Methods: We analyzed the high-resolution computed...

  • Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution. Wang, Jia; Wu, Nan; Zheng, Qingfeng; Feng, Yuan; Yan, Shi; Lv, Chao; Li, Shaolei; Wang, Yuzhao; Yang, Yue // Journal of Cancer Research & Clinical Oncology;Jul2014, Vol. 140 Issue 7, p1189 

    Purpose: To assess the utilities and drawbacks of the 7th edition of the TNM classification for lung cancer. Methods: Subjects included 1,469 patients who underwent pulmonary resection for primary non-small cell lung cancer. Survival characteristics were compared using the 6th and 7th editions...

  • Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer? Konopa, K. // Annals of Oncology;Oct2010 Supplement 7, Vol. 21 Issue suppl_7, pvii199 

    Adjuvant platinum-based chemotherapy represents the standard of care in fit stage II and IIIA non-small-cell lung cancer patients after surgical resection. This review discusses current knowledge on molecular prognostic and predictive tumor features for benefit from adjuvant therapies with...

  • Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery. Bradley, Amy; Marshall, Andrea; Stonehewer, Louisa; Reaper, Lynn; Parker, Kim; Bevan-Smith, Elaine; Jordan, Chris; Gillies, James; Agostini, Paula; Bishay, Ehab; Kalkat, Maninder; Steyn, Richard; Rajesh, Pala; Dunn, Janet; Naidu, Babu // European Journal of Cardio-Thoracic Surgery;Oct2013, Vol. 44 Issue 4, pe266 

    OBJECTIVES The aim of the study was to develop a multistranded pragmatic rehabilitation programme for operable lung cancer patients, that looks into feasibility, process indicators, outcome measures, local adaptability, compliance and potential cost benefit. METHODS An outpatient-based complex...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics